<DOC>
	<DOCNO>NCT02469467</DOCNO>
	<brief_summary>The purpose evaluate tolerability , safety efficacy VS-505 give meal 8 week hemodialysis patient hyperphosphatemia</brief_summary>
	<brief_title>A Dose Escalation Study VS-505 End Stage Renal Disease Patients Undergoing Hemodialysis</brief_title>
	<detailed_description>This study consist 4 period ; 1 ) screen period : 30 day , 2 ) first washout period : 2 week ( remove exist phosphate binder effect ) , 3 ) treatment period : 8 week , 4 ) second washout period : 2 week ( remove VS-505 effect ) . VS-505 orally administer meal 8 week . The start dose VS-505 1.50 g/day dose elevate step wise 1.50 g 2.25 g , 4.50 g 6.75 g per day base safety assessment plasma Pi level every 2 week treatment period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Written inform consent give Able comply study procedure medication On stable hemodialysis ( HD ) regimen ( 3 time per week ) include hemodialysis hemodiafiltration ≥12 week screen study period No change prescribe dose frequency follow medication within 4 week prior screen 1 . Injectable iron agent 2 . Oral injectable active vitamin D3 3 . Oral nutritional vitamin D 4 . Calcimimetics 5 . Calcium supplement 6 . Antiosteoporotic medication include bisphosphonates 7 . Calcitonins Must willing avoid intentional change diet throughout study Women childbearing potential nonsterile male subject sexually active nonsterile female partner must agree use highly effective contraception Plasma Pi level &gt; 1.94 mmol/L ( 6.0 mg/dL ) &lt; 3.23 mmol/L ( 10.0 mg/dL ) 2 week washout qualify patient enter treatment period Blood purification therapy HD ( hemodialysis hemodiafiltration ) The plasma Pi level &gt; 2.26 mmol/L ( 7.0 mg/dL ) within late three test prior screen . Variation plasma Pi 0.65 mmol/L ( 2.0 mg/dL ) within late three test prior screen . Preemptive schedule renal transplant History hemochromatosis ferritin ≥1000 mcg/L Oral iron agent include prescribed overthecounter drug screen . Current clinically significant gastrointestinal ( GI ) disorder , include GI bleeding , colitis , inflammatory bowel disease , irritable bowel syndrome , chronic constipation , new diagnosis peptic duodenal ulcer disease , within 4 week prior screen History gastrectomy duodenectomy , GI tract surgery within 12 week prior screen Hypertension : Defined use predialysis vital diastolic blood pressure &gt; 110 mmHg systolic blood pressure &gt; 180 mmHg Possible parathyroid intervention include surgical parathyroidectomy percutaneous ethanol injection therapy study period Clinical evidence active malignancy and/or receive systemic chemotherapy/radiotherapy exception basal cell squamous carcinoma skin Severe cardiovascular disorder recent myocardial infarction ; unstable angina ; congest heart failure ( NYHA class II ) hospitalize within 24 week ( 6 month ) , valve stenosis , atrial fibrillation arrhythmia History event cerebrovascular disease cardiovascular disease within 24 week ( 6 month ) prior screen Active infection current treatment antibiotic within 2 week prior screen History HIV ( ELISA Western blot ) test result Known active liver disease aspartate aminotransferase alanine aminotransferase level great x3 upper limit normal Hepatitis B and/or hepatitis C treat antiviral treatment within 4 week prior screen History allergy VS505 related component Receipt investigational drug within 4 week prior screen Pregnant breastfeed woman Other patient opinion investigator ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>phosphate binder</keyword>
	<keyword>dialysis</keyword>
</DOC>